Novel Small-Molecule Inhibitors Of The Protein Kinase Dyrk: Potential Therapeutic Candidates In Cancer
Venkataramani, P.; Elkayam, E.; Garg, A.; Cheng, K. F.; Altiti, A.; He, M.; Thakur, K.; Michalopoulou, E.; Gonzalez, C.; Van Aelst, L.; Pappin, D.; Joshua-Tor, L.; Al-Abed, Y.; Tonks, N. K.
Show abstract
Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) is crucial for normal brain development and its disruption has been linked to various cancers. DYRK1A drives glioblastoma (GBM) progression via stabilization of epidermal growth factor receptor (EGFR). Here we describe two, selective, benzothiazole-derived DYRK inhibitors, FC-2 and FC-3, obtained by structure-activity optimization of a natural product lead. Both compounds inhibit DYRK1A with nanomolar potency and display high selectivity across a kinase panel. The co-crystal structure of FC-3 with DYRK1A revealed ATP-competitive binding, with interactions at the hinge region and the DYRK-specific phenylalanine gatekeeper residue explaining target selectivity. Generation of inhibitor-resistant mutants confirmed DYRK1A as the primary cellular target. In GBM cell-models, FC-2 and FC-3 impaired neurosphere self-renewal, cell invasion, and EGFR stability, phenocopying DYRK1A loss. Both compounds crossed the blood-brain barrier and suppressed tumor growth, to prolong survival in intracranial xenografts. These findings identify FC-2 and FC-3 as selective small-molecule inhibitors of DYRK1A with potential therapeutic utility in GBM.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Discovery of a new class of reversible TEA-domain transcription factor inhibitors with a novel binding mode 95%
- Stereo-specific Lasofoxifene Derivatives Reveal the Interplay between Estrogen Receptor Alpha Stability and Antagonistic Activity in ESR1 Mutant Breast Cancer Cells 95%
- Discovery and characterization of a specific inhibitor of serine-threonine kinase cyclin dependent kinase-like 5 (CDKL5) demonstrates role in hippocampal CA1 physiology 95%
Similar papers in this journal
Similar papers in this journal
- Development of pyrazolopyrimidine based macrocyclic kinase inhibitors targeting AAK1 96%
- CHI3L1-Targeted Small Molecules as Glioblastoma Therapies: Virtual Screening-Based Discovery, Biophysical Validation, Pharmacokinetic Profiling, and Evaluation in Glioblastoma Spheroids 95%
- Targeted Degradation of METTL3 Against Acute Myeloid Leukemia and Gastric Cancer. 94%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.